58536 Federal Register / Vol. 69, No. 189 / Thursday, September 30, 2004 / Notices 

Drug Schedule 

Ethylmorphine (9190) ................................................................................................................................................................................ II 

Hydrocodone (9193) .................................................................................................................................................................................. II 

Levomethorphan (9210) ............................................................................................................................................................................ II 

Levorphanol (9220) .................................................................................................................................................................................... II 

Isomethadone (9226) ................................................................................................................................................................................. II 

Meperidine (9230) ...................................................................................................................................................................................... II 

Meperidine intermediate-A (9232) ............................................................................................................................................................. II 

Meperidine intermediate-B (9233) ............................................................................................................................................................. II 

Meperidine intermediate-C (9234) ............................................................................................................................................................. II 

Metazocine (9240) ..................................................................................................................................................................................... II 

Methadone (9250) ..................................................................................................................................................................................... II 

Methadone intermediate (9254) ................................................................................................................................................................ II 

Metopon (9260) ......................................................................................................................................................................................... II 

Morphine (9300) ........................................................................................................................................................................................ II 

Thebaine (9333) ........................................................................................................................................................................................ II 

Dihydroetorphine (9334) ............................................................................................................................................................................ II 

Opium, raw (9600) ..................................................................................................................................................................................... II 

Opium tincture (9630) ................................................................................................................................................................................ II 

Opium powdered (9639) ............................................................................................................................................................................ II 

Levo-alphacetylmethadol (9648) ............................................................................................................................................................... II 

Oxymorphone (9652) ................................................................................................................................................................................. II 

Phenazocine (9715) ................................................................................................................................................................................... II 

Piminodine (9730) ...................................................................................................................................................................................... II 

Racemethorphan (9732) ............................................................................................................................................................................ II 

Racemorphan (9733) ................................................................................................................................................................................. II 

Alfentanil (9737) ......................................................................................................................................................................................... II 

Remifentanil (9739) ................................................................................................................................................................................... II 

Sufentanil (9740) ....................................................................................................................................................................................... II 

Carfentanil (9743) ...................................................................................................................................................................................... II 

Bezitramide (9800) .................................................................................................................................................................................... II 

Fentanyl (9801) .......................................................................................................................................................................................... II 

Moramide-intermediate (9802) .................................................................................................................................................................. II 

The company plans to manufacture 

small quantities of bulk material for use 

in reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Accustandard Inc. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Accustandand Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed.

Dated: September 16, 2004

William J. Walker, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration.

[FR Doc. 04–21955 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Gilbert C. Aragon, Jr., D.O.; Revocation 

of Registration 

On January 5, 2004, the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

administration (DEA), issued an Order 

to Show Cause to Gilbert C. Aragon, Jr., 

D.O. (Dr. Aragon) notifying him of an 

opportunity to show cause as to why 

DEA should not revoke his Certificate of 

Registration, BA4652714, and deny any 

pending applications for renewal or 

modification of such registration, 

pursuant to 21 U.S.C. 824(a)(2) and (3), 

21 U.S.C. 823(f). Specifically, the Order 

to Show Cause alleged in relevant part, 

the following: 

1. Effective May 17, 2002, the Texas 

State Board of Medical Examiners 

(Board) suspended Dr. Aragon’s state 

medical license. The suspension was 

based upon an Agreed Order 

documenting Dr. Aragon’s arrest by 

Dallas Police on November 20, 2000, for 

driving while intoxicated and 

possession of dangerous and controlled 

substances. After a plea agreement with 

local authorities, Dr. Aragon pled guilty 

to the charge of driving while 

intoxicated. Court documents also 

revealed that Dr. Aragon also admitted 

guilt to the offense of illegal drug 

possession, but the matter was not 

adjudicated. On June 8, 2001, Dr. 

Aragon was sentenced to 150 days in 

jail, which was probated for two years, 

and ordered to pay a $2,000 fine. The 

Board’s suspension was further 

premised on Dr. Aragon’s admission to 

police of having written fictitious 

prescriptions in the names of family 

members in order to assist his wife (who 

was addicted to drugs) illegally obtain 

hydrocodone. As a result of the actions 

taken by the Board, Dr. Aragon is 

currently without authority to handle 

controlled substances in Texas, the State 

in which he is registered with DEA. 

2. On November 30, 2000, May 12, 

2001, and November 27, 2001, Dr. 

Aragon answered ‘‘no’’ to questions on 

his Medical Practice Questionnaire and 

Annual Registration Renewal forms 

inquiring if he had been arrested, 

charged or convicted of a crime or 

placed on probation. 

3. After being indicted by a Dallas 

County Grand Jury on January 22, 2003, 

Dr. Aragon appeared before the 203rd 

Judicial District Court of Dallas County, 

Texas, and pled guilty to the third 

degree felony of ‘‘[u]nlawfully obtaining 

from a legally registered pharmacist, a 

controlled substance, to-wit: 

dihydrocodeinone, by the use of false or 

forged prescription on October 15, 

Federal Register / Vol. 69, No. 189 / Thursday, September 30, 2004 / Notices 58537

2001.’’ The court imposed a ten year 

penitentiary sentence, five years 

community supervision as well as a 

$4,000 fine and a fifteen day jail 

sentence as a condition of community 

supervision. In response to these 

matters, on September 25, 2003, the 

Board Staff filed a Complaint requesting 

a hearing on its merits and requesting 

that Dr. Aragon’s medical license be 

suspended or revoked. 

4. Dr. Aragon’s state medical license 

has been delinquent for non-payment 

since December 30, 2002, and his Texas 

Department of Public Safety Controlled 

Substances Registration expired on 

January 31, 2003, and has not been 

renewed. 

The Order to Show Cause was 

initially sent by certified mail to Dr. 

Aragon at his registered location in 

Irving, Texas; however, the order was 

returned to DEA by the United States 

Postal Service with a stamped notation: 

‘‘attempted, not known.’’ On February 6, 

2004, DEA mailed copies of the Order 

to Show Cause to Dr. Aragon at a 

residential location in Las Vegas, New 

Mexico, with an additional copy sent to 

a purported work address in Santa Rosa, 

New Mexico. The order sent to the 

purported work address was returned 

unclaimed, but the second order sent to 

the residential location was accepted on 

behalf of Dr. Aragon on February 9, 

2004. DEA has not received a request for 

hearing or any other reply from Dr. 

Aragon or anyone purporting to 

represent him in this matter. 

Therefore, the Deputy Administrator 

of DEA, finding that (1) thirty days 

having passed since the delivery of the 

Order to Show Cause to the registrant’s 

address of record, as well as to a second 

address, and (2) no request for hearing 

having been received, concludes that Dr. 

Aragon is deemed to have waived his 

hearing right. See David W. Linder, 67 

FR 12579 (2002). After considering 

material from the investigative file in 

this matter, the Deputy Administrator 

now enters her final order without a 

hearing pursuant to 21 CFR 1301.43(d) 

and (e) and 1301.46. 

The Deputy Administrator finds that 

Dr. Aragon is currently registered with 

DEA as a practitioner. According to 

information in the investigative file, on 

or about May 15, 2002, Dr. Aragon 

entered into an Agreed Order with the 

Texas State Board of Medical Examiners 

(Board). Dr. Aragon and the Board 

agreed, inter alia, that Dr. Aragon’s state 

medical license be suspended until he 

completed various terms and conditions 

for reinstatement, including the 

completion of a 96-hour inpatient 

evaluation, conducted by or under the 

direction of a psychiatrist to evaluate 

Dr. Aragon for substance abuse or an 

organic mental condition. The Agreed 

Order resulted from findings by the 

Board that on November 20, 2000, Dr. 

Aragon was arrested by the Dallas 

(Texas) Police and charged with driving 

while intoxicated (DWI).

In addition, the Board found that Dr. 

Aragon was charged with illegal 

possession of dangerous and controlled 

substances. The Agreed Order also 

referenced Dr. Aragon’s subsequent plea 

agreement with the Dallas District 

Attorney’s Office, where he plead guilty 

and was convicted of the DWI offense. 

The Agreed Order further referenced Dr. 

Aragon’s admission of guilt to ‘‘the 

unadjudicated [sic] offenses of illegal 

drug possession, and his subsequent 

sentencing on June 8, 2001 to ‘‘150 days 

in jail probated for two years and a 

$2,000.00 fine.’’ The Board made 

additional findings regarding Dr. 

Aragon’s writing of fictitious 

prescriptions in the names of family 

members and leaving blank 

prescriptions for the use of his 

physician assistants when he was not in 

the office. 

Information in the investigative file 

also shows Dr. Aragon’s state medical 

license has been delinquent for nonpayment since December 30, 2002, and 

his Texas Department of Public Safety 

Controlled Substances Registration 

expired on January 31, 2003, and has 

not been renewed. 

There is no evidence before the 

Deputy Administrator that Dr. Aragon 

has satisfied the conditions of the Board 

for reinstatement of his medical license, 

or that the Board suspension order has 

been stayed or lifted. Moreover, there is 

no evidence in the investigative file that 

Dr. Aragon’s state controlled substance 

privileges have been renewed, or 

otherwise reinstated. 

Pursuant to 21 U.S.C. 824(a), the 

Deputy Administrator may revoke a 

DEA Certificate of Registration if she 

finds that the registrant has had his state 

license revoked and is no longer 

authorized to dispense controlled 

substances or has committed such acts 

as would render his registration 

contrary to the public interest as 

determined by factors listed in 21 U.S.C. 

823(f). Thomas B. Pilkowski, D.D.S., 57 

FR 28538 (1992). Nevertheless, despite 

findings of the Board regarding Dr. 

Aragon’s inappropriate conduct with 

respect to use of alcohol and his 

unlawful possession of dangerous and 

controlled substances, and 

notwithstanding the other public 

interest factors for the revocation of his 

DEA registration asserted herein, the 

more relevant consideration here is the 

present status of Dr. Aragon’s state 

authorization to handle controlled 

substances. 

DEA does not have statutory authority 

under the Controlled Substances Act to 

issue or maintain a registration if the 

applicant or registrant is without state 

authority to handle controlled 

substances in the state in which he 

conducts business. See 21 U.S.C. 

802(21), 823(f) and 824(a)(3). This 

prerequisite has been consistently 

upheld. See Rory Patrick Doyle, M.D., 69 

FR 11655 (2004); Dominick A. Ricci, 

M.D., 58 FR 51104 (1993); Bobby Watts, 

M.D., 53 FR 11919 (1988). 

Here, it is clear that Dr. Aragon’s 

Texas medical license has been 

suspended, his state controlled 

substance registration has expired, and 

as a result, he is currently not licensed 

under Texas law to handle these 

products. Therefore, he is not entitled to 

a DEA registration in that state. As a 

result of a finding that Dr. Aragon lacks 

state authorization to handle controlled 

substances, the Deputy Administrator 

concludes that it is unnecessary to 

address further whether his DEA 

registration should be revoked based 

upon the public interest grounds 

asserted in the Order to Show Cause. 

See Samuel Silas Jackson, D.D.S., 67 FR 

65145 (2002); Nathaniel-Aikens-Afful, 

M.D., 62 FR 16871 (1997); Sam F. 

Moore, D.V.M. 58 FR 14428 (1993). 

Accordingly, the Deputy 

Administrator of the Drug Enforcement 

Administration, pursuant to the 

authority vested in her by 21 U.S.C. 823 

and 824 and 28 CFR 0.100(b) and 0.104, 

hereby orders that DEA Certificate of 

Registration, BA4652714, issued to 

Gilbert C. Aragon, Jr., D.O., be, and it 

hereby is, revoked. The Deputy 

Administrator further orders that any 

pending applications for renewal or 

modification of such registration be, and 

they hereby are, denied. This order is 

effective November 1, 2004.

Dated: September 8, 2004. 

Michele M. Leonhart, 

Deputy Administrator.

[FR Doc. 04–21961 Filed 9–29–04; 8:45 am] 

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

Rodolfo D. Bernal, M.D.; Revocation of 

Registration 

On December 8, 2003, the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration (DEA), issued an Order 

to Show Cause to Rodolfo D. Bernal, 

M.D. (Dr. Bernal), proposing to revoke